Notice of Closed Meeting, 102910 [2024-30021]
Download as PDF
<![CDATA[
khammond on DSK9W7S144PROD with NOTICES
102910
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Food and Drug Administration
Notice of Closed Meeting
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–OH–25–003, Occupational Safety
and Health Training Project Grants
(TPG).
Date: March 4, 2025.
Time: 12:00 p.m.–5:00 p.m., EST.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Marilyn Ridenour, B.S.N., M.P.H.,
Scientific Review Officer, Office of
Extramural Programs, National Institute
for Occupational Safety and Health,
Centers for Disease Control and
Prevention, 1095 Willowdale Road,
Morgantown, West Virginia 26505.
Telephone: (304) 285–5879; Email:
MRidenour@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
PAR 18–812, NIOSH Member Conflict
Review.
Date: February 6, 2025.
Time: 1 p.m.–3 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Michael Goldcamp, Ph.D., Scientific
Review Officer, Office of Extramural
Programs, National Institute for
Occupational Safety and Health, Centers
for Disease Control and Prevention,
1095 Willowdale Road, Morgantown,
West Virginia 26505. Telephone: (304)
285–5951; Email: MGoldcamp@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Reclassification
Petitions for Medical Devices
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–30022 Filed 12–17–24; 8:45 am]
[FR Doc. 2024–30021 Filed 12–17–24; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:09 Dec 17, 2024
Jkt 265001
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
[Docket No. FDA–2024–N–2844]
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Submit written comments
(including recommendations) on the
collection of information by January 17,
2025.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The OMB
control number for this information
collection is 0910–0138. Also include
the FDA docket number found in
brackets in the heading of this
document.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Reclassification Petitions for Medical
Devices
OMB Control Number 0910–0138—
Extension
This information collection helps
support implementation of statutory
provisions found in sections 513(e) and
(f), 514(b), 515(b), and 520(l) of the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 360c(e) and (f), 21
U.S.C. 360d(b), 21 U.S.C. 360e((b), and
21 U.S.C. 360j(l)) pertaining to the
reclassification of medical devices.
E:\FR\FM\18DEN1.SGM
18DEN1
]]>Agencies
[Federal Register Volume 89, Number 243 (Wednesday, December 18, 2024)]
[Notices]
[Page 102910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30021]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention, pursuant to Public Law 92-
463. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--PAR 18-812, NIOSH Member Conflict
Review.
Date: February 6, 2025.
Time: 1 p.m.-3 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Michael Goldcamp, Ph.D.,
Scientific Review Officer, Office of Extramural Programs, National
Institute for Occupational Safety and Health, Centers for Disease
Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia
26505. Telephone: (304) 285-5951; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-30021 Filed 12-17-24; 8:45 am]
BILLING CODE 4163-18-P
